Jennifer Cremer

781 total citations
15 papers, 363 citations indexed

About

Jennifer Cremer is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Jennifer Cremer has authored 15 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 5 papers in Epidemiology. Recurrent topics in Jennifer Cremer's work include Cancer Immunotherapy and Biomarkers (5 papers), Hepatitis B Virus Studies (4 papers) and Hepatitis C virus research (4 papers). Jennifer Cremer is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Hepatitis B Virus Studies (4 papers) and Hepatitis C virus research (4 papers). Jennifer Cremer collaborates with scholars based in Belgium, United Kingdom and United States. Jennifer Cremer's co-authors include Peter Theuns, Gil Awada, Bart Neyns, Anne Rogiers, Robert C. Elston, Melanie Paff, Mark De Ridder, Dickens Theodore, Christophe Leys and Adrian Schembri and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Jennifer Cremer

14 papers receiving 360 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jennifer Cremer Belgium 8 120 93 86 85 73 15 363
Arighno Das United States 11 75 0.6× 75 0.8× 71 0.8× 100 1.2× 93 1.3× 26 368
Carmine Picone Italy 10 83 0.7× 214 2.3× 67 0.8× 146 1.7× 61 0.8× 36 445
A Andriani Italy 9 20 0.2× 103 1.1× 17 0.2× 30 0.4× 66 0.9× 15 262
Muthalagu Ramanathan United States 11 56 0.5× 103 1.1× 9 0.1× 22 0.3× 66 0.9× 53 390
Iwona Homa‐Mlak Poland 12 32 0.3× 72 0.8× 15 0.2× 75 0.9× 64 0.9× 37 289
Yecai Huang China 10 63 0.5× 87 0.9× 24 0.3× 97 1.1× 41 0.6× 34 289
Martina Haberecker Switzerland 9 49 0.4× 135 1.5× 22 0.3× 75 0.9× 84 1.2× 29 319
Shigeru Mikami Japan 11 181 1.5× 32 0.3× 213 2.5× 38 0.4× 16 0.2× 30 307
Musleh S. Tarawneh Jordan 10 74 0.6× 107 1.2× 37 0.4× 56 0.7× 32 0.4× 21 306
Natsuko Tsuda Japan 11 312 2.6× 47 0.5× 299 3.5× 18 0.2× 18 0.2× 18 465

Countries citing papers authored by Jennifer Cremer

Since Specialization
Citations

This map shows the geographic impact of Jennifer Cremer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Cremer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Cremer more than expected).

Fields of papers citing papers by Jennifer Cremer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Cremer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Cremer. The network helps show where Jennifer Cremer may publish in the future.

Co-authorship network of co-authors of Jennifer Cremer

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Cremer. A scholar is included among the top collaborators of Jennifer Cremer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Cremer. Jennifer Cremer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Cremer, Jennifer, Robert C. Elston, Fiona Campbell, et al.. (2023). B-Clear Phase 2b Study Design: Establishing the Efficacy and Safety of Bepirovirsen in Patients with Chronic Hepatitis B Virus Infection. Advances in Therapy. 40(9). 4101–4110. 1 indexed citations
2.
Bouquet, Jérôme, Robert C. Elston, Phil Yates, et al.. (2023). Frequency of bepirovirsen binding site nucleotide polymorphisms at baseline and impact on end of treatment response to bepirovirsen (Phase 2b B-Clear study). Journal of Hepatology. 78. S1162–S1162. 1 indexed citations
3.
Han, Kelong, Hiroshi Ito, Robert C. Elston, et al.. (2022). Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region. Antimicrobial Agents and Chemotherapy. 67(1). e0090022–e0090022. 3 indexed citations
4.
Yuen, Man‐Fung, Jeong Heo, Jung‐Hwan Yoon, et al.. (2021). Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nature Medicine. 27(10). 1725–1734. 102 indexed citations
5.
Rogiers, Anne, Christophe Leys, Adrian Schembri, et al.. (2020). Neurocognitive Function, Psychosocial Outcome, and Health‐Related Quality of Life of the First‐Generation Metastatic Melanoma Survivors Treated with Ipilimumab. Journal of Immunology Research. 2020(1). 2192480–2192480. 31 indexed citations
6.
Awada, Gil, Jennifer Cremer, Julia Katharina Schwarze, et al.. (2020). Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). Journal for ImmunoTherapy of Cancer. 8(2). e001146–e001146. 42 indexed citations
7.
Rogiers, Anne, Jennifer Cremer, Gil Awada, et al.. (2019). Emotional disturbances, social outcome and neurocognitive function in advanced melanoma survivors treated with pembrolizumab. Journal of Translational Medicine. 17. 7. 1 indexed citations
8.
Rogiers, Anne, Christophe Leys, Jennifer Cremer, et al.. (2019). Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study. Supportive Care in Cancer. 28(7). 3267–3278. 47 indexed citations
9.
Han, Kelong, Jennifer Cremer, Robert C. Elston, et al.. (2019). A Randomized, Double‐Blind, Placebo‐Controlled, First‐Time‐in‐Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects. Clinical Pharmacology in Drug Development. 8(6). 790–801. 34 indexed citations
10.
Rogiers, Anne, Gil Awada, Julia Katharina Schwarze, et al.. (2019). Emotional and cognitive disturbances in long-term melanoma survivors treated with ipilimumab.. Journal of Clinical Oncology. 37(8_suppl). 97–97.
11.
Neyns, Bart, Gil Awada, Jennifer Cremer, et al.. (2019). GLIAVAX: A stratified phase II clinical trial of avelumab and axitinib in patients with recurrent glioblastoma.. Journal of Clinical Oncology. 37(15_suppl). 2034–2034. 11 indexed citations
12.
Duerinck, Johnny, Stephanie Du Four, Gil Awada, et al.. (2018). Safety of axitinib plus avelumab in patients with recurrent glioblastoma.. Journal of Clinical Oncology. 36(15_suppl). e14082–e14082. 4 indexed citations
13.
Rogiers, Anne, et al.. (2018). Psychosocial outcome and health-related quality of life (HRQoL) in advanced melanoma survivors.. Journal of Clinical Oncology. 36(7_suppl). 162–162. 3 indexed citations
14.
Böning, Andreas, et al.. (2010). Octogenarians Undergoing Combined Aortic Valve Replacement and Myocardial Revascularization: Perioperative Mortality and Medium-Term Survival. The Thoracic and Cardiovascular Surgeon. 58(3). 159–163. 14 indexed citations
15.
Serruys, Patrick W., Felix Unger, Ben A. van Hout, et al.. (1999). The ARTS study (Arterial Revascularization Therapies Study).. PubMed. 4(4). 209–19. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arighno Das Breakdown of academic impact, for papers by Carmine Picone Breakdown of academic impact, for papers by A Andriani Breakdown of academic impact, for papers by Muthalagu Ramanathan Breakdown of academic impact, for papers by Iwona Homa‐Mlak Breakdown of academic impact, for papers by Yecai Huang Breakdown of academic impact, for papers by Martina Haberecker Breakdown of academic impact, for papers by Shigeru Mikami Breakdown of academic impact, for papers by Musleh S. Tarawneh Breakdown of academic impact, for papers by Natsuko Tsuda
Rankless by CCL
2026